Brief: Unicycive Achieves Primary Endpoint In Pivotal Bioequivalence Study Of Renazorb
28/12/2022 13:56
Dec 28 (Reuters) - Unicycive Therapeutics Inc UNCY.O :
* UNICYCIVE ACHIEVES PRIMARY ENDPOINT IN PIVOTAL
BIOEQUIVALENCE
STUDY OF RENAZORB
* UNICYCIVE THERAPEUTICS INC - ON TRACK TO FILE NEW DRUG
APPLICATION MID-2023
* UNICYCIVE THERAPEUTICS INC - RENAZORB DEMONSTRATES
PHARMACODYNAMIC BIOEQUIVALENCE TO FOSRENOL
* UNICYCIVE THERAPEUTICS INC - NAZORB'S ENHANCED PRODUCT
PROFILE
FEATURES REDUCED PILL BURDEN & SMALL, SWALLOWABLE TABLETS, WHICH
MAY IMPROVE PATIENT COMPLIANCE
Source text for Eikon: ID:nGNX62ThcY
Further company coverage: UNCY.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Unicycive Therapeutics
See all newsBrief: Unicycive Therapeutics Appoints Meredith Manning To Board Of Directors
Brief: Unicycive Therapeutics Announces Resubmission Of New Drug Application For Oxylanthanum Carbonate
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
Unicycive rises on narrower quarterly loss